/
Oncology
Metastatic Cancer
33
Pipeline Programs↗
34
Active Trials↗
34
Companies Involved↗
Metastatic Cancer is a moderately active landscape with 33 programs across 34 companies. The most active players are Salubris Biotherapeutics Inc, Tachyon Therapeutics, Inc., Biocity Biopharmaceutics Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 113
Phase 217
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
24 of 32 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 97% of 33 pipeline programs.
Analysis
Trial Status
147
clinical trials
Completed74 · 50%
Recruiting22 · 15%
Terminated22 · 15%
Active, not recruiting9 · 6%
Unknown status9 · 6%
Withdrawn4 · 3%
Other7 · 5%
Clinical Trials
Trial Activity
147 trials
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)